6827.TWO MegaPro Biomedical Co., Ltd

Healthcare Biotechnology Taiwan OTC Exchange
13.40 TWD
Close of Nov 6, 2026
9.47 16.80
Market cap
TWD 1.06B
P/E
-
P/B
5.03x
ROE
-45.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6827.TWO undervalued?

Graham number

The Graham number of MegaPro Biomedical Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MegaPro Biomedical Co., Ltd fundamental analysis

No fundamental analysis for MegaPro Biomedical Co., Ltd yet.

MegaPro Biomedical Co., Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MegaPro Biomedical Co., Ltd

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 20…

Full company profile